Objective:To explore the clinical and salivary metabolic component characteristics of patients with OSA combined with LPRD, and to investigate the potential co-morbid mechanisms of LPRD and OSA.Methods:A total of 98 adult patients with OSA (81 males and 17 females) who visited the Department of Otolaryngology of Peking University Third Hospital from March 2024 to May 2024 were consecutively included. The age ranged from 19 to 68 years (mean±standard deviation: 39.44±11.39 years). The severity of OSA was grouped according to the apnea-hypopnea index (AHI) [mild group (29 cases), moderate group (26 cases), and severe group (43 cases)]. Patients with a reflux symptom index score (RSI)>13 points and/or a reflux sign score (RFS)>7 points were considered LPRD positive. Among the 98 OSA patients, 48 had LPRD and 50 did not. All patients were diagnosed with OSA through out of center sleep testing(OCST) or polysomnography (PSG), and general information, laryngoscopic examination images, and RSI scales were collected. The RFS was evaluated based on the laryngoscopic examination results. Saliva samples were collected from both groups for metabolomics analysis. Chi-square test was used for categorical variable comparison, and independent sample t-test or one-way ANOVA analysis of variance was used for continuous variable comparison.Results:Stratified analysis showed that the proportion of male patients in the mild OSA group was significantly lower than that in the moderate or severe OSA groups (58.6%, 92.3%, 93.0%, χ2=16.43, P<0.001), and the BMI was significantly lower in the mild OSA group [(25.80±4.41)kg/m 2, (27.53±3.88)kg/m 2, (28.99±3.65)kg/m 2, F=6.91, P=0.002]. There was no statistically significant difference in the prevalence of LPRD among patients with different severity of OSA. The BMI of OSA patients with LPRD was higher than that of patients with OSA alone [(28.65±4.75)kg/m 2, (26.94±3.16)kg/m 2, t=-2.07, P=0.041], but there were no statistically significant differences in gender composition, age, AHI, and minimum blood oxygen saturation between the two groups. The metabolomics results of saliva samples from both groups showed significant differences in the levels of tryptophan pathway metabolites. The salivary serotonin metabolite level in patients with LPRD combined with OSA was significantly lower than that in patients with OSA alone (relative abundance 0.12±0.019 vs 0.22±0.046, t=2.04, P=0.045). Conclusion:Patients with OSA combined with LPRD have a greater BMI and significantly lower serotonin, a tryptophan metabolite component of saliva, which may be a potential co-morbidity mechanism between OSA and LPRD.

Objective:To explore the clinical and salivary metabolic component characteristics of patients with OSA combined with LPRD, and to investigate the potential co-morbid mechanisms of LPRD and OSA.Methods:A total of 98 adult patients with OSA (81 males and 17 females) who visited the Department of Otolaryngology of Peking University Third Hospital from March 2024 to May 2024 were consecutively included. The age ranged from 19 to 68 years (mean±standard deviation: 39.44±11.39 years). The severity of OSA was grouped according to the apnea-hypopnea index (AHI) [mild group (29 cases), moderate group (26 cases), and severe group (43 cases)]. Patients with a reflux symptom index score (RSI)>13 points and/or a reflux sign score (RFS)>7 points were considered LPRD positive. Among the 98 OSA patients, 48 had LPRD and 50 did not. All patients were diagnosed with OSA through out of center sleep testing(OCST) or polysomnography (PSG), and general information, laryngoscopic examination images, and RSI scales were collected. The RFS was evaluated based on the laryngoscopic examination results. Saliva samples were collected from both groups for metabolomics analysis. Chi-square test was used for categorical variable comparison, and independent sample t-test or one-way ANOVA analysis of variance was used for continuous variable comparison.Results:Stratified analysis showed that the proportion of male patients in the mild OSA group was significantly lower than that in the moderate or severe OSA groups (58.6%, 92.3%, 93.0%, χ2=16.43, P<0.001), and the BMI was significantly lower in the mild OSA group [(25.80±4.41)kg/m 2, (27.53±3.88)kg/m 2, (28.99±3.65)kg/m 2, F=6.91, P=0.002]. There was no statistically significant difference in the prevalence of LPRD among patients with different severity of OSA. The BMI of OSA patients with LPRD was higher than that of patients with OSA alone [(28.65±4.75)kg/m 2, (26.94±3.16)kg/m 2, t=-2.07, P=0.041], but there were no statistically significant differences in gender composition, age, AHI, and minimum blood oxygen saturation between the two groups. The metabolomics results of saliva samples from both groups showed significant differences in the levels of tryptophan pathway metabolites. The salivary serotonin metabolite level in patients with LPRD combined with OSA was significantly lower than that in patients with OSA alone (relative abundance 0.12±0.019 vs 0.22±0.046, t=2.04, P=0.045). Conclusion:Patients with OSA combined with LPRD have a greater BMI and significantly lower serotonin, a tryptophan metabolite component of saliva, which may be a potential co-morbidity mechanism between OSA and LPRD.

Animals ; Macaca mulatta ; Optic Disk ; Glaucoma ; Craniocerebral Trauma ; Intraocular Pressure ; Low Tension Glaucoma

The incidence of single-sided deafness（SSD） is increasing year by year. Due to the hearing defects of one ear, the ability of sound localization, speech recognition in noise, and quality of life of patients with single-sided deafness will be affected to varying degrees. This article reviews the intervention effects of different types of bone conduction hearing aids in patients with single-sided deafness and asymmetric hearing loss, and the differences of intervention effects between bone conduction hearing aids, contralateral routing of signal（CROS） aids, and cochlea implant（CI）, to provide a reference for the auditory intervention and clinical treatment of single-sided deafness and asymmetric hearing loss.
Humans ; Quality of Life ; Bone Conduction ; Hearing Loss, Unilateral/therapy* ; Speech Perception ; Hearing Aids ; Hearing Loss ; Sound Localization ; Deafness ; Treatment Outcome

[Abstract] Objective: To investigate the expression of chemokine-like factor-like MARVEL transmembrane domain-containing family member 6 (CMTM6) in breast cancer tissues and its correlation with clinicopathological features and prognosis of patients. Methods:Atotal of 136 breast cancer tissue chips (purchased from Superchip Company), including 42 pairs of matched cancer and paracancerous tissues, were used for this study. The expression level of CMTM6 in cancer and paracancerous tissues was detected by immunohistochemistry. The comparison of CMTM6 expression between breast cancer and paracancerous tissues was conducted by paired χ2 test. The relationship between CMTM6 expression in breast cancer tissues and the clinicopathological characteristics of patients was analyzed by χ2 test. Kaplan-Meier and Log rank test analyses were used to analyze the relationship between CMTM6 expression and the survival of patients, and Cox model was used to evaluate the effect of different indicators on the prognosis of patients. Results: The expression of CMTM6 in breast cancer tissues was significantly higher than that in paracancerous tissues (P<0.01). The expression of CMTM6 was correlated with pathological type of breast cancer and HER2 positivity (P<0.05). The survival time of patients in CMTM6 high expression group was significantly shorter than that of patients in CMTM6 low expression group (P<0.05). Pathological type (HR=10.374, 95%CI: 3.529-30.497, P<0.01), TNM stage (HR=4.599, 95%CI: 1.784-11.856, P<0.01), triple-negative breast cancer (HR=3.370, 95%CI: 1.055-10.761, P<0.05) and high expression of CMTM6 (HR=0.195, 95%CI: 0.073-0.518, P<0.01) were independent risk factors for prognosis of breast cancer patients. Conclusion: CMTM6 is highly expressed in breast cancer tissues, which can be used as a risk factor for prognosis evaluation of breast cancer patients.